Report copyright - ORIGINAL ARTICLE Adalimumab discontinuation in of the ...Figure 1 Study designs of HOPEFUL-1 and HOPEFUL-2. The HOPEFUL-1 study comprised a 26-week randomised phase (ADA + MTX (intensive
Please pass captcha verification before submit form